Chronic Granulomatous Disease (CGD) is a rare genetic disorder that affects the immune system, specifically the ability of phagocytes to produce reactive oxygen species (ROS) necessary for ...

“Based on data from our preclinical studies, we believe PM359 has the potential to sufficiently correct a prevalent disease-causing mutation of CGD, leading to amelioration of disease for these ...

Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.

Prime Medicine’s lead candidates are PM359 for chronic granulomatous disease (CGD), which was recently awarded rare paediatric disease designation (RPDD) by the FDA, along with candidates for ...